Therapeutic HIV vaccines: An update

Current HIV/AIDS Reports

Volumn 2, Issue 1, 2005, Pages 5-9

  Lévy, Yves ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Human Immunodeficiency Virus; Human Immunodeficiency Virus Infection; Human Immunodeficiency Virus Type; Plasma Viral Load; Virologic Failure

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; VIRUS REPLICATION;

AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS; VIRUS REPLICATION;

EID: 25144471319     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-996-0002-5     Document Type: Article

References (43)

1. Borrow P, Lewicki H, Hahn BH, et al.: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:6103–6110.
2. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650–4655.
3. Rosenberg ES, Billingley JM, Caliendo AM, et al.: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447–1450. DOI: 10.1126/science.278.5342.1447
4. Cao Y, Qin L, Zhang L, et al.: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995, 332:201–208. DOI: 10.1056/NEJM199501263320401
5. Lieberman J, Shankar P, Manjunath N, Andersson J: Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 2001, 98:1667–1677. DOI: 10.1182/blood.V98.6.1667
6. Appay V, Nixon DF, Donahoe SM, et al.: HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000, 192:63–75. DOI: 10.1084/jem.192.1.63
7. Goepfert PA, Bansal A, Edwards BH, et al.: A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol 2000, 74:10249–10255. DOI: 10.1128/JVI.74.21.10249-10255.2000
8. Champagne P, Ogg GS, King AS, et al.: Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001, 410:106–111. DOI: 10.1038/35065118
9. Carcelain G, Tubiana R, Samri A, et al.: Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001, 75:234–241. DOI: 10.1128/JVI.75.1.234-241.2001
10. Autran B, Carcelain G, Combadiere B, Debre P: Therapeutic vaccines for chronic infections. Science 2004, 305:205–208. DOI: 10.1126/science.1100600
11. Tubiana R, Gomard E, Fleury H, et al.: Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity. AIDS 1997, 11:819–820.
12. Sandrom E, Wahren B: Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomized double-blind placebo-controlled trial. Nordic VAC-04 study group. Lancet 1999, 353:1735–1742. DOI: 10.1016/S0140-6736(98)06493-9
13. Schooley RT, Spino C, Kuritzkes D, et al.: Two double-blinded, randomized, comparative trial of four human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS clinical trials groups 209 and 214. J Infect Dis 2000, 182:1357–1364. DOI: 10.1086/315860
14. Kahn JO, Cherng DW, Mayer K, et al.: Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 106/L CD4 cell counts: a randomized controlled trial. JAMA 2000, 284:2193–2202. DOI: 10.1001/jama.284.17.2193
15. Jin X, Gao X, Ramanathan Jr M, et al.: Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 2002, 76:2206–2216. DOI: 10.1128/jvi.76.5.2206-2216.2002
16. Markowitz M, Jin X, Hurley A, et al.: Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002, 186:634–643. DOI: 10.1086/342559
17. Rosenberg ES, Altfeld M, Poon SH, et al.: Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523–526. DOI: 10.1038/35035103
18. Valdez H, Connick E, Smith KY, et al.: Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002, 16:1859–1866. DOI: 10.1097/00002030-200209270-00002
19. Oxenius A, Price DA, Gunthard HF, et al.: Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002, 99:13747–13752. DOI: 10.1073/pnas.202372199
20. Ortiz GM, Nixon DF, Trkola A, et al.: HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999, 104:13–18. DOI: 10.1172/JCI7371
21. Harrer E, Bauerle M, Ferstl B, et al.: Analysis of Nef-specific T-cells, viral rebound and autologous viral sequences during structured treatment interruption after therapeutic vaccination with a MVABN-Nef vaccine in HIV-1-infected patients on HAART [abstract]. Paper presented at the 10th Conference on Retrovirus and Opportunistic Infections. Boston, MA, February 10–14, 2003.
22. Robbins GK, Addo MM, Troung H, et al.: Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS 2003, 17:1121–1126. DOI: 10.1097/00002030-200305230-00002
23. Kran AM, Sorensen B, Nyhus J, et al.: HLA-and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004, 18:1875–1883. DOI: 10.1097/00002030-200409240-00003
24. Sha BE, Onorato M, Bartlett JA, et al.: Safety and immunogenicity of a polyvalent peptide CA-V3 HIV vaccine in conjunction with IL-12. AIDS 2004, 18:1203–1216. DOI: 10.1097/00002030-200405210-00015
25. Boström AC, Hejdeman B, Matsuda R, et al.: Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV). Vaccine 2004, 22:1683–1691. DOI: 10.1016/j.vaccine.2003.09.049
26. Hejdeman B, Bostrom AC, Matsuda R, et al.: DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy. AIDS Res Hum Retrovirus 2004, 20:860–870. DOI: 10.1089/0889222041725190
27. Tubiana R: Therapeutic Vaccination with ALVAC-HIV vCP1433: A Recombinant Canarypox Vaccine in Chronically HIV-1 Infected Patients Treated with HAART: VACCITER (ANRS 094) [abstract]. Paper presented at the 10th Conference on Retrovirus and Opportunistic Infections. Boston, MA, February 10–14, 2003.
28. Kinloch S, Perrin L, Hoen B, et al.: Evaluation of two therapeutic HIV vaccination regimens in HAART-treated primary HIV infection subjects following analytical treatment interruption: QUEST PROB3005, a randomized, placebo-controlled study [abstract]. Paper presented at the 11th Conference on Retrovirus and Opportunistic Infections. San Francisco, CA, February 8–11, 2004.
29. Cooper D, Workman C, Puls R, et al.: Randomized, placebocontrolled, phase 1/2a evaluation of the safety, biological activity and antiretroviral properties of an avipox virus vaccine expressing HIV gag-pol and interferon-g in HIV-1 infected subjects [abstract]. Paper presented at the 11th Conference on Retrovirus and Opportunistic Infections. San Francisco, CA, February 8–11, 2004.
30. Goujard C, Marcellin F, Chavez H, et al.: HIV immune and virological responses following the administration of IL-2 either alone or combined to ALVAC-HIV 1433 and HIV lipopeptides in patients treated early with HAART during primary infection: the ANRS 095 randomized study [abstract]. Paper presented at the 11th Conference on Retrovirus and Opportunistic Infections. San Francisco, CA, February 8–11, 2004.
31. Levy Y, Gahery-Segard H, Durier C, et al.: Immunological and virological efficacy of a therapeutic immunization combined with Interleukin-2 in chronically HIV-1 infected patients. AIDS 2005, In press. This randomized study demonstrates a containment of viral replication through therapeutic immunization after HAART withdrawal in chronically infected patients.
32. Fernandez-Cruz E, Moreno S, Navarro J, et al.: Therapeutic immunization with an inactivated HIV-1 immunogen plus antiretrovirals versus therapy alone in asymptomatic HIV-infected subjects. Vaccine 2004, 22:2966–2973. DOI: 10.1016/j.vaccine.2004.03.040
33. Chantratita W, Sukeepaisarncharoen W, Chandeying V, et al.: Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand. HIV Med 2004, 5:317–325. DOI: 10.1111/j.1468-1293.2004.00230.x
34. Lu W, Arraes LC, Ferreira WT, Andrieu JM: Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004. Epub ahead of print.
35. Klinguer C, David D, Kouach M, et al.: Characterization of a multilipopeptides mixture used as an HIV-1 vaccine candidate. Vaccine 1999, 18:259–267. DOI: 10.1016/S0264-410X(99)00196-6
36. Moss RB, Giermakowska WK, Savary JR, et al.: A primer on HIV type-1-specific immune function and REMUNE. AIDS Res Hum Retroviruses 1998, 2(Suppl):S167–175.
37. Turner JL, Kostman JR, Aquino A, et al.: The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cells counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med 2001, 2:65–67. DOI: 10.1046/j.1468-1293.2001.00051.x
38. Trauger RJ, Ferre F, Daigle AE, et al.: Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994, 169:1256–1264.
39. Limsuwan A, Churdboonchart V, Moss RB, et al.: Safety and immunogenicity of REMUNE in HIV-infected Thai subjects. Vaccine 1998, 16:142–149. DOI: 10.1016/S0264-410X(97)88327-2
40. Lederman MM, Douek DC: Sometimes help may not be enough. AIDS 2003, 17:1249–1251. DOI: 10.1097/00002030-200305230-00018
41. Lichterfeld M, Kaufmann DE, Yu XG, et al.: Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 2004, 200:701–712. This study shows that HIV-specific IL-2 secreting CD4 T cells elicited by therapeutic immunization may correct in vitro the functional defect of cytotoxic T lymphocytes from chronically HIV infected patients. DOI: 10.1084/jem.20041270
42. Goh LE, Perrin L, Hoen B, et al.: Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: The QUEST study. HIV Clin Trials 2001, 2:438–444. DOI: 10.1310/7V45-PHYR-8BU6-DLUN
43. Levy Y, Durier C, Lascaux AS, et al.: Extended follow-up of the ANRS 093 randomized study: evaluation of of ALVAC-VIH 1433 and HIV lipopeptides (Lipo-6T) combined with SC IL-2 in chronically HIV-infected patients [abstract]. Paper presented at the 2nd IAS Conference on HIV pathogenesis and treatment. Paris, France, July 13–17, 2003.